Answers are grounded in this paper and cite their sources.
Observational analysis revealed significant outcomes in relapsed or refractory follicular lymphoma patients, highlighting favorable survival rates.
Summary Relmacabtagene autoleucel (relma‐cel) demonstrated significant clinical outcomes for ≥3 lines of treatment for relapsed or refractory (R/R) follicular lymphoma (FL) in the RELIANCE study. The primary end‐point was the complete response rate (CRR) at 3 months. Key secondary end‐points included the duration of response (DOR), progression‐free survival (PFS), overall survival (OS) and frequency/severity of adverse events (AEs). Relma‐cel‐treated patients ( N = 28) had a median age of 54 years (range: 36–71 years), and more than 60% of the patients received ≥3 lines of prior systemic therapies. The median follow‐up was 24.4 months. As previously reported, in the primary analyses set ( n = 27), the 3‐month CRR was 85.2% and the 3‐month overall response rate was 100.0%. The median DOR, PFS and OS were not reached. As updated in this article, the estimated 2‐year PFS and OS rates were 80.3% and 100% respectively. During the 90‐day treatment‐emergent period ( N = 28), no patients had cytokine release syndrome of grade ≥3, and neurological toxicity of grade ≥3 occurred in only one patient treated with 100 × 10 6 chimeric antigen receptor T cells. Neutropenia (39.3%) was the most common grade ≥3 treatment‐emergent adverse event. There were no AEs leading to death. Relma‐cel demonstrated durable remissions and manageable safety without new safety signals during the 2‐year follow‐up in patients with R/R FL ( ClinicalTrials.gov , NCT04089215).
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: